Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash & Current Investments (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Cash & Current Investments for 6 consecutive years, with $77.3 million as the latest value for Q3 2025.

  • Quarterly Cash & Current Investments rose 2283.81% to $77.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $77.3 million through Sep 2025, up 2283.81% year-over-year, with the annual reading at $138.6 million for FY2024, 945.52% up from the prior year.
  • Cash & Current Investments for Q3 2025 was $77.3 million at Inhibikase Therapeutics, down from $87.7 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $138.6 million in Q4 2024, with the low at $3.2 million in Q3 2024.
  • Average Cash & Current Investments over 5 years is $39.7 million, with a median of $26.5 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments soared 601525.64% in 2021, then plummeted 80.73% in 2024.
  • Over 5 years, Cash & Current Investments stood at $40.8 million in 2021, then tumbled by 43.44% to $23.1 million in 2022, then tumbled by 42.51% to $13.3 million in 2023, then soared by 945.52% to $138.6 million in 2024, then plummeted by 44.19% to $77.3 million in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $77.3 million, $87.7 million, and $93.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.